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Protease inhibitors (PIs) of hepatitis C virus (HCV) provide an additional or alternative therapy for chronic
infection. However, assessment of their efficacy and ability to inhibit replication of different genotypes is
hampered by the lack of a convenient animal model or a method for in vitro culture of HCV other than the type
1/2-based replicons and the infectious genotype 2a clone JFH1. To address this problem, we constructed a
panel of replication-competent chimeric Jc1 (pFK JFH1/J6/C-846) clones containing protease and NS4A
coding sequences from all six major genotypes, enabling the determination of replication and the susceptibility
to PIs. Chimeras showed substantial variability in replication kinetics, attributable in part to naturally
occurring polymorphisms and differing requirements for adaptive mutations in NS3 and NS4A. Through
calculation of 50% inhibitory concentrations (IC50s) of BILN 2061, measuring reduction in the number of
focus-forming units/ml (FFU/ml) and replication inhibition, consistent genotype-associated differences in
antiviral susceptibilities were observed. IC50s for genotype 1b, 4a, and 6a-derived chimeras (1 to 3 nM) were
approximately 100-fold lower than those for genotypes 2a, 3a, and 5a (range, 80 to 720 nM), implying major
differences in response to therapy. In vitro passage in increasing concentrations of BILN 2061 rapidly induced
resistance-associated mutations at position 168 in chimeras of all 6 genotypes and at position 156 in genotypes
1b and 4a, each with substantial variability in the identity of substituted amino acids. The system will allow
future comprehensive phenotypic characterization of naturally occurring and treatment-induced mutations for
PIs in trial or entering clinical use.
Worldwide, about 170 million individuals are estimated to
be infected with hepatitis C virus (HCV) (1, 48). Chronic HCV
infection is a leading cause of chronic liver diseases, such as
cirrhosis and hepatocellular carcinoma (6). HCV has a posi-
tive-sense, single-stranded RNA genome of approximately
9,600 nucleotides, belonging to the family Flaviviridae (7). A
single polyprotein of around 3,000 amino acids (53) is trans-
lated and processed by cellular and viral proteases to generate
10 different structural and nonstructural proteins (16, 18, 19).
The error-prone RNA-dependent RNA polymerase (RdRp)
NS5B, and the resulting high mutation frequencies during rep-
lication, contributes to the substantial genetic and antigenic
heterogeneity of HCV, with seven major genotypes showing
30% nucleotide sequence divergence from each other and
numerous subtypes identified to date (5, 50–52). The distribu-
tion of genotypes varies by geographical location and risk
groups for infection; the predominant genotypes within the
United States, Europe, Australia, and East Asia (Japan, Tai-
wan, Thailand, and China) are 1, 2, and 3. Genotype 4 is largely
confined to the Middle East, Egypt, and Central Africa,
whereas genotypes 5 and 6 are found predominantly in South
Africa and Southeast Asia, respectively (49).
The current treatment of pegylated interferon and ribavirin
has limited efficacy and serious side effects; infections with
genotype 1 in particular respond poorly even to prolonged
treatment, with 48% failing to clear infections after 48 weeks of
combined therapy (33, 39). To address this problem, several
direct antiviral inhibitors of the NS3/4A serine protease and
the RNA-dependent RNA polymerase have been developed.
Among the former are the noncovalent inhibitor BILN 2061
(24) and the covalent inhibitors SCH 503034 (30) and VX-950
(37). In ongoing trials, encouraging results have been reported
for the covalent inhibitors (12, 17, 42, 44), whereas the non-
covalent inhibitor BILN 2061 development has been halted
due to cardiotoxicity in laboratory animals (58) (reviewed re-
cently by de Bruijne et al. [9]).
Research into antiviral drugs and vaccines has been ham-
pered by the lack of a full viral life cycle cell culture system.
Only recently, a full-length HCV cell culture system in which
infectious virus can be generated in Huh7 cells from transfec-
tion of complete HCV genomic RNA sequences has been
described (26, 59). Viable JFH1-based intergenotypic recom-
binants containing genotype-specific structural proteins (core,
E1, and E2), p7, and NS2 have been developed for all seven
genotypes (14, 15, 21, 38, 45, 65), which allow the study of
vaccines and entry inhibitors for all genotypes. However, full-
length HCV cell culture systems allowing the study of the NS3
protease are currently available only for genotypes 2a (JFH1
and HC-J6) (26, 34, 59) and 1a (H77), which needs adaptive
mutations to replicate efficiently (64). The limited number of
replication-competent full-length reference sequences limits
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the assessment of how genetic variation between the different
genotypes and within subtypes influences susceptibility to an-
tiviral therapy and development of resistance.
The aim of the current study was to develop effective cell
culture systems for the six major genotypes of HCV, to com-
pare the susceptibility of each to the protease inhibitor (PI),
BILN 2061, and through passaging in subinhibitory concentra-
tions of the drug, to compare the ability and mechanism of
antiviral resistance development between genotypes. The use
of replicon vectors, where protease genes of different geno-
types were inserted into the genotype 1b replicon, has been
demonstrated in several reports (3, 40). Other approaches
involve the release of reporter molecules upon NS3/4A cleav-
age (29). None of these methods, however, construct infectious
virus that would allow the whole replication cycle of HCV to be
analyzed.
Recently, the full-length replication-competent clone Jc1
(pFK JFH1/J6/C-846) has been developed. This clone com-
prises the HCJ6 core and envelope coding sequences and a
portion of the NS2 gene, with the remainder of the polyprotein
derived from JFH1 (26, 38). It replicates autonomously and
yields high infectious titers in the Huh7.5 cells. It was therefore
chosen as a backbone for the construction of the intra- and
intergenotypic recombinants in the current study and enabled
the activities of HCV protease inhibitors against different ge-
notypes and diverse natural isolates to be directly assessed.
The development of these replication-competent intergeno-
type chimeras will improve the ability to predict clinical doses,
efficacy, and development of drug resistance mutations in a
diverse range of HCV variants circulating worldwide.
MATERIALS AND METHODS
HCV plasmids, sequences, and clinical specimens. pJFH1 and pJFH1-GND
(AB047639), used in the construction of the intra- and intergenotypic recombi-
nants, were provided by T. Wakita (Tokyo Metropolitan Institute for Neuro-
science, Tokyo, Japan) (59), and pFK JFH1/J6/C-846_dg (Jc1) was provided by
R. Bartenschlager (Department of Molecular Virology, University of Heidel-
berg, Heidelberg, Germany) (38). pJ6CF (GenBank accession no. AF177036)
and pH 77* (differs from pH 77 [GenBank accession no. AF011751] at M1205T)
were provided by J. Bukh (NIH, Hepatitis Viruses Section, National Institutes of
Health, Bethesda, MD) (62, 63), and HCV3a-Gla (p3a) was provided by E. A.
McCruden (Division of Virology, Institute of Biomedical and Life Sciences,
University of Glasgow, Glasgow, United Kingdom) (47). HC-J4 (p1b, D10750)
was described by Okamoto et al. (35). ED43* (p4a) differs from ED43 (GenBank
accession no. NC_009825) by 4 amino acids (T1048A, T1064I, I1160T, and
R1176A), EUH1480* (p5a) differs from EUH1480 (GenBank accession no.
NC_009826) by 9 amino acids (L1045V, F1061V, I1072T, L1081V, K1117T,
G1118R, R1122P, I1694V, and T1695I), and EUHK2* (p6a) differs from
EUHK2 (GenBank accession no. Y12083) by 6 amino acids (D1065A, V1070L,
P1085A, F1087S, K1094R, and I1196V). Plasmids p4a, p5a, and p6a were pro-
vided by Richard Elliot (Centre for Biomolecular Sciences, University of St.
Andrews, St. Andrews, United Kingdom). Differences between clones and pro-
totype sequences were present in received clones and likely arose during cloning.
Sequences of HCV isolates used for sequence diversity analysis were retrieved
from the HCV sequence database (22) and the NCBI GenBank. A total of 570
NS3 and NS4A sequences of genotype 1a, 459 NS3 sequences of genotype 1b,
242 NS3 and 180 NS4A sequences of genotype 3a, 39 NS3 sequences of genotype
4a, and 15 NS3 sequences of genotype 6a were analyzed. Anonymized research
samples of residual plasma from previous investigations of HCV epidemiology
and treatment response were used for estimation of sequence diversity in NS3.
Cell culture. Huh7.5 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) supplemented with 4,500 mg/liter glucose, 2 mM
L-glutamine, 10% heat-inactivated fetal calf serum (FCS; Harlan Sera-Lab),
nonessential amino acids, 20 mM HEPES, 100 U/ml penicillin, and 100 g/ml
streptomycin and incubated at 37°C, 5% CO2, and 100% relative humidity. Cells
were split every second to third day at a ratio of 1:2 to 1:3.
Construction of pJFH1- and Jc1-based intra- and intergenotypic recombi-
nants. (i) Replacement of the NS3 protease gene (Fx/Jx). All nucleotide positions
are referred to according to their position in the H77 reference position,
AF009606. To construct F1a, F1b, F2a, F3a, F4a, F5a, and F6a, a BstBI restric-
tion site was generated at the junction of NS2 and NS3 in the pJFH1 plasmid,
and a BglII restriction enzyme site was generated at the junction of the NS3
protease and NS3 helicase domain. To reduce the possibility of PCR errors, the
NS3 gene was subcloned into Zero Blunt TOPO using the naturally occurring
restriction sites NotI and SpeI. A QuikChange site-directed mutagenesis kit
(Stratagene) was used to introduce two silent point mutations to generate a
BstBI site (C3398T and C3401G) and one to create a BglII restriction site
(G3993A). Each of the introduced base changes was verified by DNA sequence
analysis. The NS3 protease region was amplified from pH 77* with primers
1aBstBI and 1aBglII, of pJ6CF with primers 2aBstBI and 2aBglII, and so on. A
list of all the primers used can be found in the supplemental material (http:
//www.virus-evolution.org/Downloads/JVI02698-09/). Primers were designed to
include the JFH1 sequence of the NS2 region and the corresponding intergeno-
typic sequence of the NS3 protease region. Products were digested with BstBI
and BglII (all restriction enzymes were obtained from New England Biolabs), gel
purified (gel extraction kit; Qiagen) and ligated into pJFH1. pJFH1 has similarly
been digested with BstBI and BglII, dephosphorylated using alkaline phos-
phatase (New England Biolabs), and gel purified. Each introduced NS3 protease
gene was verified by DNA sequence analysis. To generate the corresponding
Jc1-based chimeras (Jx), recombinant plasmids were digested with NotI and SfiI,
gel purified, and ligated into Jc1, which was digested with NotI and SfiI and
dephosphorylated.
(ii) Replacement of NS3 protease and NS4A cofactor gene (Fxx/Jxx). To
generate F1a1a, F1b1b, F2a2a, F3a3a, F4a4a, F5a5a, and F6a6a, two new re-
striction sites were introduced into pJFH1. To reduce the possibility of PCR
errors, the NS4A was subcloned into Zero Blunt TOPO using the naturally
occurring restriction sites NsiI and XbaI. A BlpI restriction site was generated by
introducing a silent point mutation (C5297G) at the NS3 helicase and NS4A
junction, and a MluI site was generated by introducing 4 point mutations
(T5478A, T5480G, A5481C, G5483T) at the NS4A and NS4B junction, in which
one was nonsilent. The NS4A region was amplified from pH 77* with primers
1aSapI and 1aMluI, introducing SapI (5-end) and MluI (3-end) restriction sites.
The same strategy was used to amplify NS4A from genotype 1a to 6a prototype
plasmids, using the corresponding genotype-specific primers (primer sequences
can be found in the supplemental material at http://www.virus-evolution.org
/Downloads/JVI02698-09/). Products were digested with SapI and MluI, gel
purified, and ligated into the TOPO vector containing the JFH1 insert digested
with BlpI and MluI and dephosphorylated. A5478 was mutated back to T by
site-directed mutagenesis to recreate a native JFH1 amino acid sequence (Ala to
Thr) outside the NS4A region. To generate Fxx and Jxx, TOPO vector, including
the modified insert, was digested with NotI and SfiI, gel purified, and ligated into
pJHF1 and Jc1, respectively, which were digested with NotI and SfiI and de-
phosphorylated.
Amplification of the NS3 protease gene from study subject plasma. HCV
RNA was isolated from 150 l study subject plasma using the Qiagen RNeasy kit,
according to the manufacturer’s guidelines. Extracted RNA was eluted into 30 l
of RNase-free water. To generate cDNA and the primary PCR product, 0.75-M
genotype-specific outer primers (NS3p1a/1b/3a/4a/6aOS and NS3p1a/1b/3a/4a/
6aOA; for sequences, see the supplemental material at http://www.virus
-evolution.org/Downloads/JVI02698-09/) and 10 l of extracted RNA were used
in a 50-l reaction using the SuperScript III one-step reverse transcriptase PCR
(RT-PCR) system with Platinum Taq DNA polymerase (Invitrogen), as recom-
mended by the manufacturer. The PCR protocol consisted of an RT step at 43°C
for 1 h, followed by 20 cycles of 53°C for 1 min, 55°C for 1 min, and final
extension at 70°C for 15 min. Subsequent to a denaturation step at 94°C for 2
min, 35 cycles of 94°C for 30 s; 54°C for 30 s; 68°C for 2 min; and a final extension
at 68°C for 5 min were performed. The first-round PCR products were used as
templates in a nested secondary PCR using genotype-specific primers (1a/1b/3a/
4a/6aBstBIs and 1a/1b/3a/4a/6aBglIIas) introducing BstBI (5-end) and BglII
(3-end) restriction sites. Nested PCR was performed using the high-fidelity
KOD Hot Start polymerase (Novagen), as recommended by the manufacturer.
Each PCR product was sequenced to obtain the consensus sequence of the
corresponding NS3 protease gene. The nested PCR products were treated with
BstBI and BglII and gel purified. To remove the NS3 protease gene, Jxxs
including prototype NS3 protease genes were likewise digested with BstBI and
BglII, dephosphorylated, and gel purified. Purified study subject-derived NS3
protease genes were then ligated into the corresponding Jxx, creating interge-
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notypic chimeras where the NS3 protease gene is study subject derived and
where the NS4A cofactor has prototype sequence.
Construction of adapted genomes. RNA was extracted from infectious superna-
tant using the QIAamp viral RNA minikit (Qiagen), according to the manufacturer’s
protocol. If no infectious supernatant was generated, RNA was alternatively ex-
tracted from cell pellets using Qiagen shredder columns, followed by a Qiagen
RNeasy kit used as described above. A PCR product was generated using Super-
Script III as described above. JFH-NotI and JFH-SpeI were used to amplify a
1.2-kb-long fragment encompassing the HCV NS3 protease, and JFH-5230 and
JFH-5536 were used to amplify a 300-bp-long fragment encompassing the NS4A
cofactor. The PCR product was then subjected to bulk sequence determination. To
generate J2a2a-C3538G (J2a2a-T1066S), J5a5a-C3416G, T3968C, A4081T (J5a5a-Q1247L),
and J6a6a-A3458G, G3459T (J6a6a-V1040L), the fragment encompassing the HCV NS3
protease was digested with SpeI and NotI and cloned into the corresponding (J2a2a,
J5a5a, or J6a6a) recombinant plasmids. To generate J3a3a-3-C5328G, T5329C (J3a3a-
3-L1663A) and J3a3a-8-C5328G, T5329C (J3a3a-8-L1663A), point mutations were intro-
duced by site-directed mutagenesis and cloning. Modified fragments were verified by
sequencing.
RNA synthesis and transfection. Plasmid templates were linearized by XbaI
digestion (for pJFH1 and pJFH1 chimeras) or MluI digestion (for Jc1 and Jc1
chimeras) and treated with mung bean nuclease (New England Biolabs) to
remove 5-end overhangs. The linearized DNA template was cleaned by phenol-
chloroform extraction following ethanol precipitation. RNA was synthesized
from 1 g DNA template with T7 RNA polymerase (Promega) for 1 h at 37°C.
Following treatment with RNase-free DNase, RNA was cleaned up using the
RNeasy kit (Qiagen), and the integrity of the RNA was analyzed by nondena-
turing agarose gel electrophoresis. RNA concentrations were determined using
spectrophotometry, and 10-g aliquots were stored at 80°C.
RNA was transfected into Huh7.5 cells by electroporation. Huh7.5 cells were
washed with phosphate-buffered saline (PBS) and detached with trypsin. Cells
were pelleted by centrifugation (1,600 rpm for 7 min at 4°C), then resuspended
in 10 ml chilled diethyl pyrocarbonate (DEPC)-treated PBS, counted, washed
three times with chilled DEPC-treated PBS (1,600 rpm for 4 min at 4°C), and
then chilled on ice for at least 5 min. A total of 10 g of RNA was mixed with
5  106 cells suspended in 400 l of PBS and transferred to an electroporation
cuvette (0.4-cm gap width; Bio-Rad, Munich, Germany). Electroporation con-
sisted of one square wave pulse for 25 ms of current delivered by the Bio-Rad
Gene Pulser Xcell electroporation device, set at 150 V. Transfected cells were
immediately resuspended in 4.5-ml 50:50 dilution mix of conditioned and fresh
media (containing 10% FCS) and then transferred into T25 flasks containing 10
ml complete growth medium or seeded into 24-well plates for NS5A immuno-
staining and incubated at 37°C, 5% CO2, and 100% relative humidity. Cells were
passaged every 3 to 4 days by trypsinization and reseeding with a 1:3 to 1:4 split
ratio into fresh culture vessels or 24-well plates for NS5A immunostaining.
Virus-containing supernatant was collected, cleared of cell debris by centrifuga-
tion, and stored at 4°C overnight or at 80°C for the long term.
Immunohistochemistry staining for HCV NS5A. Viral replication was assessed
by NS5A staining. Electroporated cells were seeded into 24-well plates contain-
ing coverslips and immunostained for NS5A when they were subconfluent. Fol-
lowing fixation of cells in 4% paraformaldehyde for 20 min, cells were washed
three times with PBS and then permeabilized using 0.1% Triton X-100 in PBS for
7 min. Following 2 further washes with PBS, cells were incubated with an
in-house-derived polyclonal sheep anti-NS5A serum (provided by Mark Harris,
University of Leeds) diluted 1:5,000 in 10% FCS-PBS for 1 h. After cells were
washed two times with PBS, bound NS5A-specific antibody was detected by 1 h
of incubation with Alexa Fluor 488 donkey anti-sheep IgG (Invitrogen) diluted
1:1,000 in PBS. Cells were further washed two times before NS5A-positive cells
were detected using a fluorescence microscope. Three images per coverslip were
taken from two coverslips per sample, and the percentage of HCV-positive cells
was determined using AxioVision 4.8 software, where 0% shows that no cells are
infected and 100% shows that all cells are infected. Jc1 served as a positive
control, and JFH1-GND served as a negative control.
Determination of TCID50 in HCV cultures. Naïve Huh7.5 cells were seeded in
96-well plates the previous day at a concentration of 6  103 cells/well. The
sample was serially diluted in complete growth medium and inoculated onto the
cells at 10-fold dilutions, with 6 replicates at each dilution. After 3 days of
incubation, cells were stained for NS5A as described above. Viral titers were
determined by calculating the tissue culture infectious dose at which 50% of the
wells were positive for viral antigen (TCID50). Wells were scored positive if at
least 1 positive cell was detected. TCID50 was calculated according to the method
of Reed and Muench (41).
Drug inhibition studies. The HCV-specific protease inhibitor (PI) BILN 2061
was resuspended at 5 mM in dimethyl sulfoxide (DMSO). Naïve Huh7.5 cells
were seeded in 96-well plates the previous day at a concentration of 6  103
cells/well. The next day, cells were infected for 8 h with the corresponding
infectious supernatant at a multiplicity of infection (MOI) of 0.015 and washed
with PBS, and the medium was replaced with complete growth medium contain-
ing 0.1% DMSO, as a carrier control, with or without the indicated concentra-
tions of the PI. Cultures were incubated for 3 days and then stained for NS5A as
described above. Each concentration was assayed in triplicate. The percent
inhibition of supernatant infectivity was calculated from the reduction in the
number of FFU/ml after antiviral addition compared to the number of FFU/ml
in virus control without antiviral addition.
Alternatively, 10 g synthetic RNA was electroporated into Huh7.5 cells as
described above and seeded into 24-well plates. The next day, the medium was
replaced with complete growth medium containing 0.1% DMSO with or without
the indicated concentrations of PI. Cultures were incubated for a further 3 days
and then stained for NS5A as described above. Antiviral efficacy was measured
as the inhibition of RNA replication by staining for NS5A and determining the
percentage of HCV-positive cells. Each concentration was assayed in triplicate.
For J2a2a, 1 g instead of 10 g was used to achieve an infection frequency of
around 40%. For J6a6a, cells were first passaged for 24 days to allow 40% of the
culture to be infected before BILN 2061 was added.
Dose-response curves were fitted to a four-parameter logistic function to
obtain 50% maximal inhibitory concentrations (IC50s) using SigmaPlot.
In vitro selection of BILN 2061-resistant recombinant viruses. Synthetic RNA
of the recombinant viruses J1b1b, J2a2a-T1066S, J3a3a, J4a4a-19, J5a5a-V1040L,
and J6a6a was electroporated into Huh7.5 cells as described above and seeded
into 12-well plates. At 3 (J1b1b, J3a3a, and J4a4a-19) or 4 (J2a2a-T1066S and
J5a5a-Q1247L) days postelectroporation, BILN 2061 was added, and the cells
serially passaged under increasing BILN 2061 concentrations (from 23 nM to 230
nM for J1b1b, from 500 nM to 1000 nM for J2a2a-T1066S, from 350 nM to 7000
nM for J3a3a, from 10 nM to 100 nM for J4a4a-19, 500 nM for J5a5a-Q1247L, and
from 1 nM to 10 nM for J6a6a; see Table S5 in the supplemental material at
http://www.virus-evolution.org/Downloads/JVI02698-09/). J6a6a was first pas-
saged for 35 days before antiviral addition. During the course of selection,
infected cells were split when 70 to 80% confluence was reached. Fresh medium
and BILN 2061 were added every 3 or 4 days, regardless of whether the cell
culture was split. Whenever the cell culture was split, cell pellets were collected,
and total cellular RNA was extracted and subjected to RT-PCR as described
above. To determine the frequency of BILN 2061 resistance mutations, the
1.2-kb-long RT-PCR products of HCV RNA were ligated into the TOPO cloning
vector, and individual bacterial colonies were subjected to colony PCR and
sequenced. Each passaging experiment was carried out in duplicate and with a
parallel passage containing control without antiviral.
Nucleotide sequence accession numbers. Sequences obtained in the course of
the study have been submitted to GenBank and have been assigned accession no.
GU945424 to GU945462.
RESULTS
Design and construction of intra- and intergenotypic recom-
binants containing heterologous NS3 protease. Intergenotype
chimeras containing the NS3 protease gene of heterologous
genotypes were created through ligation of protease domain
sequences from different genotypes into the Jc1 backbone se-
quence. This necessitated creation of two unique restriction
sites, a BstBI site at the 5 end and a BglII site at the 3 end of
the protease-encoding region, creating the Jc1-BB clone. This
showed the same replication kinetics as the parental strain Jc1
(Fig. 1). Protease genes from genotypes 1a (H77*), 1b (HC-
J4), 2a (J6CF), 3a (HCV3a-Gla), 4a (ED43*), 5a (EUH1480*),
and 6a (EUHK2*) were amplified by PCR and cloned into
Jc1-BB. Recombinants containing heterologous proteases
were termed Jx, where “x” identifies the genotype of the pro-
tease domain (Fig. 2A). RNAs transcribed from the recombi-
nant plasmids and the replication-defective pJFH1-GND and
Jc1 were electroporated into the highly permissive Huh7.5
cells, and virus replication was assessed by NS5A immunostain-
ing. Besides J2a, which showed replication kinetics similar to
that of the parental Jc1, only J5a replicated to detectable
VOL. 84, 2010 DEVELOPMENT OF INTERGENOTYPIC HCV CELL CULTURE METHOD 4599
levels, and it took 20 days to spread to 50% of the cell culture
(Fig. 2B). As the cell culture was split through the course of the
experiment, the virus would have had to spread to neighboring
cells to achieve this infection frequency during passaging.
Design and construction of intra- and intergenotypic recom-
binants containing heterologous NS3 protease and NS4A co-
factor. Since the NS4A cofactor is an indispensable part of the
NS3 protease function and highly variable in sequence between
genotypes, we investigated whether inclusion of the homolo-
gous NS4A gene in the intragenotypic/intergenotypic recom-
binants improved their replication ability (2, 11, 54).
Two unique restriction sites were introduced at the 5 end
(BlpI) and at the 3 end (MluI) of NS4A, and the correspond-
ing NS4A genes from genotypes 1a, 1b, 2a (pJ6CF), 3a, 4a, 5a,
and 6a were amplified by PCR using primers with SapI and
MluI restriction sites. The primers were designed to include
the JFH1 sequence up to the start of the NS4A gene (nucle-
otide [nt] 5313) and then the corresponding genotype se-
quence to the 3 end of NS4A (nt 5474). As the introduction of
the MluI restriction site was not synonymous, it was reversed to
the JFH1 amino acid sequence after NS4A gene insertion by
site-directed mutagenesis. The corresponding intragenotypic/
intergenotypic recombinants containing the NS3 protease and
NS4A gene sequences of hetero- or homologous genotypes
were termed Jxx, where “xx” stands for the corresponding
genotype in the protease and NS4A regions, respectively (Fig.
3 and 4A).
Replication-competent recombinants could be created with
genotypes 1b, 2a, 3a, 5a, and 6a (Fig. 4B to G). Four days after
transfection, J1b1b was detected in 50% of the cell culture but
was then cleared from the cell culture, likely reflecting an
inability to infect Huh7.5 cells de novo beyond the transfection
stage. In marked contrast, J2a2a and J5a5a replication was
detected in almost all cells 2 days after transfection, compara-
ble to that of Jc1. The immediate spread of these recombinants
and Jc1 was accompanied by increased cell death, followed by
proliferation of HCV-NS5A-negative Huh7.5 cells, as de-
scribed in previous studies (14). Both, however, start to re-
spread in the cell culture after this initial decrease in infected
cell frequency, indicating sequence changes that reduce the
cytopathic effect of the virus and promote its survival in cell
culture. We have termed these changes as “attenuating” to
make clear the difference with conventional “adaptive” muta-
tions that enhance replication ability.
Replicating J3a3a and J6a6a viruses were found in 80% of
the cell culture after an eclipse phase of 6 and 33 days, respec-
tively. Compared to other Jxx recombinants, where the per-
centage of NS5A-positive cells was reduced again after an
eclipse phase, J3a3a still infected 80% of the cell culture 70
days postelectroporation, indicating continuous spread to un-
infected cells. Supernatant infectivity was measured at the
peak of the infection by determining TCID50s (Table 1). The
highest infectivity titer was measured for J2a2a, with a
TCID50/ml of 10
4.2. J1b1b did not secrete any detectable in-
fectious virus into the supernatant (32, 45, 66). J1a1a and
J4a4a were not viable or their replication was not efficient
enough to be detected with our assay. However, replacement
of the NS3 protease gene in J4a4a with that of study subject-
derived protease genes generated the replication-competent
recombinants J4a4a-7, -8, and -19 (see next section) (Fig. 4E
and 5C). J4a4a-7 and J4a4a-19 showed a replication profile
similar to that of J1b1b, with NS5A-positive cells initially de-
tected in 50% of the cell culture but then cleared out as the
culture was passaged. As with J1b1b, no infectious virus was
secreted into the supernatant. J1a1a and J4a4a both differ from
the prototype sequences of H77 and ED43 by 1 (H77-M1205T)
and 4 (ED43-T1048A, T1064I, I1160T, R1176A) amino acids, respec-
tively, in the protease gene, whereas J1a1a and J4a4a are
FIG. 2. Jx recombinants and their viability in Huh7.5 cells. (A) Ge-
nome map of cDNA clones (pJ6CF, gray; pJFH1, white). The NS3
protease was replaced with the corresponding intra- or intergenotypic
gene (replaced region, black). UTR, untranslated region. (B) RNA
transcripts from J1a, J1b, J2a, J3a, J4a, J5a, and J6a were electropo-
rated into Huh7.5 cells, and replication was assessed by immunostain-
ing against NS5A. Jc1 and pJFH1-GND served as positive and nega-
tive controls, respectively. Transcripts from the J1a, J1b, J3a, J4a, and
J6a clones showed no detectable replication (all values lying on the x
axis line).
FIG. 1. Replication kinetics in Huh7.5 cells of the parental JFH1
and Jc1 full-length RNA transcripts and comparison with that of
Jc1-BB containing introduced BstBI and BglII restriction sites in NS3
for protease gene insertion. The replication-defective mutant JFH1-
GND was used as a negative control. The y axis records the percentage
of HCV NS5A-positive cells scored by fluorescence microscopy.
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identical to H77 and ED43, respectively, in the NS4A gene
(see Fig. S2 in the supplemental material at http://www.virus
-evolution.org/Downloads/JVI02698-09/). M1205 is predomi-
nant among genotype 1a isolates, although one of the 601
available sequences of other genotype 1a isolates contained the
Thr residue at this site, one contained Val, and one contained
Ile. A total of 4 of 459 genotype 1b isolates in the HCV
database contained the Thr residue at this position as well,
largely discounting this substitution as a cause of the poor
replication ability of the J1a1a clone.
Replication kinetics of J1a1a, J1b1b, J3a3a, J4a4a, and
J6a6a containing NS3 protease genes derived from HCV-in-
fected study subjects. We investigated whether the differing
replication kinetics of chimeras constructed from different ge-
notypes were a consistent genotype-associated property or
whether it originated from naturally occurring variability be-
tween HCV variants within a genotype. For this purpose, we
constructed chimeras from protease genes amplified from mul-
tiple study subjects infected with genotypes 1a, 1b, 3a, 4a, and
6a that showed markedly different replication kinetics and abil-
ities to generate infectious virus (Fig. 4; Table 1). For each
genotype, chimeras were created using PCR-amplified pro-
tease sequences from epidemiologically unlinked subjects in-
fected with genotypes 1a, 1b, 3a, 4a, and 6a.
In an initial survey of 33 HCV variants recovered from
genotype 3a-infected individuals, amplified protease gene se-
quences showed 6.9 and 2.7% nucleotide and amino acid se-
quence divergence, respectively, from each other, consistent
with previous analyses of genotype 3a variability within this
genome region (27, 60) (see Fig. S1B in the supplemental
material at http://www.virus-evolution.org/Downloads/JVI02698
-09/). From these 33 consensus sequences, the protease genes
from three study subjects were used to replace the protease do-
main of J3a3a-Gla. Clones containing amino acid polymorphisms
not found in any other sequence in the Los Alamos HCV se-
quence database, GenBank, or the consensus sequences in our
data set were discarded (see Fig. S2B [http://www.virus-evolution
.org/Downloads/JVI02698-09/]), ensuring representation of nat-
urally occurring polymorphism. All three constructs yielded
replicating virus but with different replication kinetics (Fig.
5B). J3a3a-11 replication was detected in most cells on day 9,
slightly earlier than that with J3a3a-Gla. J3a3a-8 and J3a3a-3
spread occurred after an eclipse phase of 28 days.
It was unclear whether the differences in the replication kinet-
ics of the J3a3a chimeras represented different degrees of com-
patibility between the subject-derived protease sequences with
the NS4A cofactor sequence derived from the reference strain or
whether there were specific compatibility problems with the ge-
notype 2a backbone sequence. To investigate this, we compared
the NS4A sequences of the prototype (HCV3a-Gla) with those of
the three subjects (see Fig. S2B in the supplemental material at
http://www.virus-evolution.org/Downloads/JVI02698-09/). All
J3a3a recombinants’ NS4A cofactor sequences were identical
at the amino acid level, except for an L1670I amino acid sub-
stitution in the J3a3a-11 recombinant. L1670 is dominant
among genotype 3a isolates, although 14 sequences with Val
and 3 with Phe were identified among the 180 isolates ana-
lyzed. These observations indicate that incompatibility be-
tween the NS3 protease and the prototype HCV3a-Gla NS4A
is most likely not a determinant for the observed differences in
the replication kinetics of the J3a3a recombinants.
By the same methods, J1a1a recombinants with subject-
derived proteases were created. NS3 protease sequences ob-
tained from 31 subjects infected with genotype 1a showed 7.6
FIG. 3. Comparison of genotype 1a, 1b, 2a, 3a, 4a, 5a, and 6a NS3 protease and NS4A cofactor sequences. (A) Alignment of NS3 protease
residues (in black) from recombinants J1a1a, J1b1b, J2a2a, J3a3a, J4a4a, J5a5a, and J6a6a to JFH1 (NCBI accession no. AB047639). (B) Align-
ment of NS4A protease cofactor residues (in black) from recombinants J1a1a, J1b1b, J2a2a, J3a3a, J4a4a, J5a5a, and J6a6a to JFH1. Dots indicate
amino acid sequence identity.
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FIG. 4. Jxx recombinants and their viability in Huh7.5 cell results from two independent experiments (Jxx_A and Jxx_B). (A) Genome map of
cDNA clones (pJ6CF, gray; pJFH1, white). The NS3 protease and NS4A were replaced with intra- and intergenotypic genes (replaced region,
black). (B to G) RNA transcripts from J1a1a, J1b1b, J2a2a, J3a3a, J4a4a-19, J5a5a, and J6a6a were electroporated into Huh7.5 cells. Jc1 and
pJFH1-GND served as positive and negative controls, respectively.
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and 2.5% nucleotide and amino acid sequence divergence,
respectively, from each other, again representing the naturally
occurring diversity of this genotype (20, 27, 57, 60) (see Fig.
S1A in the supplemental material at http://www.virus-evolution
.org/Downloads/JVI02698-09/). The replacement of the NS3
protease of J1a1a-H77* with that of genotype 1a-infected
subject-derived proteases resulted in replicating virus in 7
(J1a1a-1, -2, -3, -4, -5, -6, and -8) out of 9 recombinant viruses.
None, however, spread to more than 0.08% of the cell culture,
and all cells were NS5A negative after 30 days (data not
shown). Except for J1a1a-1, all J1a1a recombinants contained
one or more naturally occurring amino acid polymorphisms
represented among sequences of the 570 isolates available from
GenBank and the 31 isolates analyzed in this study (see Fig. S1
in the supplemental material at http://www.virus-evolution.org
/Downloads/JVI02698-09/). In contrast, J1a1a-1, which was the
recombinant showing the best replication kinetics (data not
shown), contained one amino acid substitution (G1056) that does
not occur in any other isolate analyzed. To investigate whether
the H77*-NS4A cofactor was responsible for the severally im-
paired replication fitness of the J1a1a recombinants, NS4A amino
acid sequences obtained from subjects whose proteases were used
in the recombinants were compared with that of H77*. The mem-
brane segment and the NS3 cofactor region showed amino acid
identity (see Fig. S2A [http://www.virus-evolution.org/Downloads
/JVI02698-09/]) (4). Some polymorphism occurred in the C-ter-
minal domain of the NS4A cofactor, which, however, is not in-
volved in the direct interaction with the NS3 protease. Differences
in replication kinetics between the different J1a1a recombinants
are therefore most likely due to the protease itself. Whether the
overall poor replication kinetics of the J1a1a recombinants can be
attributed to the reduced enzymatic function of the 1a proteases
or to their incompatibility with the remaining type 2a sequence
remains to be investigated.
The generation of J4a4a subject-derived protease recombi-
nants resulted in a replicating virus in three (J4a4a-7, -8, and
-9) out of four (J4a4a-7, -8, -9, and -10) recombinant viruses
(Fig. 5C). A total of 40 to 50% of all cells were positive for
NS5A at 4 days posttransfection with J4a4a-7 and J4a4a-19
RNA, whereas J4a4a-8 replicated only to very low levels.
J4a4a-ED43* (A1048 and I1064), J4a4a-7 (R1056), J4a4a-10
(P1169), and J4a4a-19 (I1153) all showed amino acid polymor-
phisms which do not exist in any other genotype 4a isolate
analyzed (n  39) (see Fig. S2 in the supplemental material at
http://www.virus-evolution.org/Downloads/JVI02698-09/). Only
recombinant J4a4a-8 shows an amino acid polymorphism that
also exists within the 4a isolates from the database. It is unclear
which amino acid polymorphism contributes to the impaired
replication phenotype in J4a4a-ED43* and J4a4a-10.
The generation of J1b1b subject-derived protease recombi-
nants resulted in replicating virus for both of the generated
recombinants (J1b1b-2 and J1b1b-12), with both showing rep-
lication kinetics similar to that of the prototype recombinant
J1b1b (Fig. 5A). The same was true for J6a6a subject-derived
protease recombinants (Fig. 5D). J6a6a-4 immediately in-
fected 70 to 80% of the cell culture, whereas J6a6a-8 took 30
days to spread to the rest of the cell culture, similar to the
prototype recombinant J6a6a.
Identification of adaptive and attenuating mutations in re-
covered Jx and Jxx viruses. J5a, J6a6a, and the subject-derived
chimeras J3a3a-3 and J3a3a-8 spread only in the cell culture after
an eclipse phase. To investigate whether the delay in replication
reflected a requirement for adaptive mutations to allow efficient
replication, we determined the nucleotide sequence from the
protease and NS4A regions amplified from cell culture superna-
tants after the chimera had spread to 80% of the cell culture
(Table 2). The gene regions from nt position 2863 to 4178, which
included the 3 end of NS2 and the 5 end of the NS3 helicase,
and nt position 5230 to 5536, including NS4A, were sequenced at
peak infectivity of the individual viruses. In the recovered ge-
nomes of passaged J3a3a-8 and J3a3a-3, no substitutions were
detected, except in NS4A, where all 5 clones analyzed had the
C5328G and T5329C substitutions, among others. The resulting
L1663A amino acid substitution only became dominant in the
J3a3a-Gla recombinant after 43 days of cell culture passaging. J5a
had two substitutions within the NS3 protease domain (A3649G
and C3854G), leading to the amino acid substitutions N1103S and
C1171W. Within the type 2a NS4A, one nucleotide substitution
(G5430A) led to the amino acid change D1679N. The J6a6a
FIG. 5. J1b1b, J3a3a, J4a4a, and J6a6a study subject-derived protease recombinants and their viability in Huh7.5 cells. The protease region of
J1b1b, J3a3a, J4a4a, and J6a6a was replaced with that of two or three study subject-derived protease genes, and their replication capacities were
assessed in the Huh7.5 cells.
TABLE 1. Supernatant infectivity titers determined by
TCID50 assay
Viral isolate Dayspostelectroporation TCID50/ml
J1b1b 5 10
J2a2a 5 104.2
J3a3a 15 103.4
J4a4a-19 5 10
J5a5a 5 101.9
J6a6a 33 102.6
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recombinant virus had two substitutions (A3558G and G3439T),
resulting in a V1040L amino acid change within the N-terminal
part of the NS3 protease. This amino acid is highly conserved
among all genotypes, allowing only Leu, Val, or Ile (4).
Both J2a2a and J5a5a replicated to high levels in cell culture,
accompanied by increased cell death. After an initial clearance of
the virus, both spread in cell culture again, indicating the acqui-
sition of attenuating mutations (Fig. 4C and F). A C3538G nu-
cleotide change within the protease domain of J2a2a leads to a
T1006S amino acid change. Within J5a5a, three nucleotide
changes (C3416G, T3968C, and A4081T), leading to a Q1247L
amino acid change, were identified (Table 2).
Recombinant adapted/attenuated viruses efficiently infect
Huh7.5 cells. To identify whether the substitutions occurring in
NS4A accounted for the differences in replication kinetics of
the J3a3a-3 and -8 recombinant viruses, mutations were intro-
duced into the original plasmids, and their viability was tested
in Huh7.5 cells. Both J3a3a-3-L1663A (J3a3a-3-mt) and J3a3a-
8-L1663A (J3a3a-8-mt) spread directly within the cell culture,
and after 11 and 17 days, respectively, almost all cells were
infected, with replication kinetics similar to those of J3a3a-Gla
and J3a3a-11 (Fig. 5B and 6D). The L1663A amino acid
(C5328G and T5329C) change at the 5 end of NS4A was
therefore sufficient to restore efficient replication. Reintroduc-
ing the V1040L amino acid change into J6a6a generated a
FIG. 6. Viability of J2a2a, J5a5a, J6a6a, and J3a3a recombinants with study subject-derived NS3 protease genes, including adaptive/attenuating
mutations observed in clonal analysis.
TABLE 2. Mutations of Jxs and Jxxs during passaging in Huh7.5 cells
HCV chimera
Mutationsa
NS3p NS3h NS4A
J5a A3649G G5430A
C3854G
J2a2a C3538G
J3a3a C5328GT5329C
J3a3a-3 all C5328GT5329C
Clones 1, 4, and 5 C5328GT5329C
Clone 2 C5328GT5329CT5365C
Clone 3 C5328GT5329CT5447C
Clone 6 C5328GT5329CT5358C
J3a3a-8
Clones 1, 4, and 5 C5328GT5329C
Clone 2 C5328GT5329C
T5389CA5434G
Clone 3 C5328GT5329CA5472G
J5a5a C3416G T3968C
A4081T
J6a6a A3458G
G3459T
a Abbreviations: NS3p, NS3 protease; NS3h, NS3 helicase. Nucleotide posi-
tions are numbered according to H77 (GenBank accession no. AF009606) ref-
erence positions.
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recombinant (J6a6a-V1040L) which showed improved replica-
tion kinetics as well (Fig. 5C). At 2 days postelectroporation,
J6a6a-V1040L replicated in 80% of the cell culture and contin-
ued to infect most of the cell culture at 14 days postelectropo-
ration. Both J2a2a and J5a5a replicated to high levels, but
replication was accompanied by increased cell death. Reintro-
duction of the identified mutations (Table 2) generated two
attenuated viruses (Fig. 6A and B). Both J2a2a-T1066S and
J5a5a-Q1247L were immediately able to infect about 80% of the
cell culture and continued to infect the majority of cells at 14
days postelectroporation.
Susceptibility of different HCV genotypes to protease inhib-
itors. Intra- and intergenotypic recombinants derived from ge-
notypes 2a, 3a, 5a, and 6a that produced infectious virus were
evaluated for protease inhibitor sensitivity. We wished to de-
termine how the activity of BILN 2061 was affected by the
sequence differences of enzymes from various genotypes (Fig.
3). Huh7.5 cells were infected with virus containing superna-
tant (MOI of 0.015), and then the reduction in the number of
FFU/ml upon BILN 2061 treatment was assessed (Fig. 7).
Supernatant infectivities of all recombinant viruses were inhib-
ited but to different extents. J2a2a, J3a3a, and J5a5a showed
similar dose responses (IC50  210 nM, 80 nM, and 110 nM,
respectively), whereas J6a6a (IC50  2 nM) was reproducibly
100-fold more susceptible to BILN 2061.
Since no infectious virus could be generated for J1b1b and
J4a4a-19, protease inhibitor susceptibility was also assessed
after synthetic RNA had been electroporated into fresh
Huh7.5 cells (Fig. 8). After 24 h, protease inhibitor was added,
and the reduction in the frequency of NS5A-positive cells was
assessed at 96 h postelectroporation. J1b1b, J4a4a-19, and
J6a6a showed 100- to 1,000-fold-greater susceptibility (IC50 
3 nM, 1 nM, and 1 nM, respectively) than J2a2a, J3a3a, and
J5a5a (IC50  720 nM, 105 nM, and 480 nM, respectively).
To investigate whether naturally occurring sequence vari-
ability within a genotype led to differences in antiviral suscep-
tibilities, the J3a3a recombinants with study subject-derived
proteases (J3a3a-3-mt, -8-mt, and -11) were subjected to BILN
2061 treatment as described above. The J3a3a-Gla chimera
generated from the HCV3a-Gla prototype sequence showed
an IC50 of 130 nM, comparable to previous assays (Fig. 8) but
2 to 3-fold lower than the IC50s of the subject-derived se-
quences (310 nM for J3a3a-11, 300 nM for J3a3a-8-mt, and 240
nM for J3a3a-3-mt) (Fig. 9). Although requiring further eval-
uation of more replicates’ antiviral dilutions to establish formal
statistical significance, these small but reproducible differences
in apparent susceptibility suggest that some of the naturally
occurring sequence variability within a subtype or genotype
might have a direct and potentially clinically significant effect
on response to antiviral therapy.
FIG. 7. Antiviral inhibition of Jxxs. Reduction in supernatant in-
fectivity. After 8 h of inoculation with Jxx (MOI, 0.015), Huh7.5 cells
were washed and incubated in media containing 0.1% DMSO, as a
carrier control, with or without the indicated doses of BILN 2061.
Inhibition was calculated at 72 h postinfection as a reduction in su-
pernatant infectivity (the number of FFU/ml; mean 	 SEM; n  3)
after antiviral (AV) addition compared to infectivity of the control
without antiviral.
FIG. 8. Antiviral inhibition of Jxxs. Reduction in viral replication.
RNA (1 to 10 g) was electroporated into Huh7.5 cells and incubated
for 24 h. Cells were then washed and incubated in media containing
0.1% DMSO, as a carrier control, with or without the indicated doses
of BILN 2061 for a further 72 h. The percent inhibition of replication
was determined at 96 h postelectroporation (mean 	 SEM; n 3) and
calculated as the ratio of NS5A-positive cells in BILN 2061-treated
cells to those of the control without antiviral.
FIG. 9. Antiviral inhibition of J3a3a recombinants with study sub-
ject-derived proteases. RNA (10 g) was electroporated into Huh7.5
cells and incubated for 24 h. Cells were then washed and incubated in
media containing 0.1% DMSO, as a carrier control, with or without the
indicated doses of BILN 2061 for a further 72 h. The percent inhibition
of replication was determined at 96 h postelectroporation (mean 	
SEM; n 3) and calculated as the ratio of NS5A-positive cells in BILN
2061-treated cells to those of the control without antiviral.
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In vitro selection of BILN 2061-resistant recombinant vi-
ruses. Chimeras constructed from HCV genotypes 1 to 6 were
passaged in initially subinhibitory but increasing concentra-
tions of BILN 2061 beyond the IC50s determined for each
genotype to investigate whether antiviral resistance could be
induced in vitro. After replicate transfection with chimeras
of each genotype, BILN 2061 was added initially at concen-
trations approximately 10% of the IC50 and increased to
final concentrations greater than the IC50 recorded for each
genotype (individual schedules are provided in Table S1 in
the supplemental material at http://www.virus-evolution.org
/Downloads/JVI02698-09/). Attenuated clones of genotypes
2a (J2a2a-T1066S) and 5a (J5a5a-Q1247L) were used to allow
long-term passage. For each genotype, control passages
without addition of BILN 2061 were performed. Every 3 or
4 days, cells were split, the medium was replenished, and
fresh BILN 2061 was added. At the end of passaging, HCV
RNA was extracted from cell pellets of each replicate and
control and subjected to RT-PCR to amplify the coding
region of the HCV NS3 serine protease domain. To delin-
eate the identity and frequency of substitutions, the RT-
PCR product from each genotype passage was subcloned
into the TOPO vector, and 10 individual colonies of two
replicates and 10 clones from the control were subjected to
sequencing.
All 6 genotypes showed substitutions at position 168, al-
though this position differed in both the identity of the wild
type-encoded amino acid and the substitutions that arose on
passaging (Table 3). In contrast, this site remained invariant in
each control passage experiment performed in parallel without
addition of BILN 2061. Genotypes 2, 3, and 5 showed complete
replacement of the wild-type codon in both replicate passages,
while replacement frequencies of genotypes 1b, 4a, and 6a
ranged from 70% to 90%. Genotypes 1b and 4a additionally
showed a further substitution of the Ala residue at position 156
for Val and Gly in a proportion of clones (Table 3). One of the
two replicates from the genotype 2a chimera showed a change
at position 195 in half of the clones analyzed. All other sub-
stitutions recorded among clones in either BILN 2061 or con-
trol passages occurred infrequently (0 to 4 among each set of
10 clones), at variable positions, and were equally frequent
among BILN 2061-passaged and control virus populations
(data not shown).
DISCUSSION
Genetic variability of HCV proteins of different genotypes
influences the molecular structure of protease and polymerase
enzymatic sites and potentially limits the effectiveness of anti-
viral therapy targeting viral replication proteins (20). For ex-
ample, BILN 2061, a protease inhibitor specifically developed
for genotype 1, shows a nearly 2 log-weaker binding affinity to
genotype 2 and 3 proteases than to genotype 1 protease (55),
a difference that translates to much weaker antiviral efficacy of
BILN 2061 among subjects with HCV genotype 2 or 3 infection
(43) than those with HCV genotype 1 infection (24). The
reduced effectiveness of antiviral drugs on certain genotypes
also potentially facilitates the development of resistance mu-
tations. Another PI, VX-950, showed similar efficacy in geno-
types 1a, 1b, and 2a but lower efficacy in genotype 3a (37, 42).
Current drug discovery and optimization are mostly depen-
dent on laboratory-optimized standard replicons. However, the
standard replicon system allows only the evaluation of a lim-
ited number of laboratory strains that do not reflect the great
genetic inter- and intragenotypic diversity of HCV. Different
replicon-based vector approaches have to date been limited to
the investigation of the activity of compounds against different
HCV isolates from genotypes 1 to 4 (3, 40). The replicon-based
system, however, does not include structural genes and there-
fore does not represent the full viral life cycle of HCV. We
describe here the development of a full-length HCV cell cul-
ture system, allowing the study of the NS3 protease of all 6
genotypes. Recombinant viruses were constructed from Jc1, an
intragenotypic genotype 2a recombinant, which replicates ef-
ficiently in the Huh7.5 cells (38). The resulting recombinant
viruses encode the NS3 protease or the NS3 protease and the
NS4A gene from genotype 1a, 1b, 2a, 3a, 4a, 5a, or 6a proto-
type strains or different clinical isolates, respectively.
The original attempt to replace the NS3 protease alone was
not successful in creating replication-competent intergenotypic
viruses, except for genotype 5a (Fig. 2B), which spread only
within the cell culture after acquiring adaptive mutations (Ta-
ble 2). Since the NS3 protease forms a stable complex with
NS4A and is required for its trans-cleavage activity (10, 11, 54,
56), we reasoned that the poor replication ability of most Jx
constructs may have originated through incompatibilities be-
tween these two protease components. It has, however, been
TABLE 3. Acquisition of mutations in NS3 during passaging in BILN 2061
Clone
BILN 2061 % remaining wild type (mutation
s)c
Genotype Conc/nMa Day Position WTb Replicate 1 Replicate 2 Control
J1b1b 1b 230 8 168 D 0 (7G, 1A, 1E, 1V) 10 (3G, 1A, 5E) 100
156 A 60 (4V) 90 (1V) 100
J2a2a-T1066S 2a 1,000 22 168 D 0 (8V, 2Y) 0 (4V, 6Y) 100
195 Q 100 40 (6H) 100
J3a3a 3a 7,000 21 168 Q 0 (4L, 5R, 1K) 0 (8L, 2K) 100
J4a4a-19 4a 100 13 168 D 20 (6G, 2V) 20 (4G, 2A, 2E) 100
156 A 80 (2V) 80 (2T) 100
J5a5a-Q1240L 5a 500 21 168 E 0 (7A, 1V, 2G) 10 (9A) 100
J6a6a 6a 10 28 168 D 30 (4V, 2E, 1H) 30 (3V, 1E, 3N) 100
a Final passage concentration of BILN 2061.
b WT, wild type.
c Proportion of clones retaining the original amino acid results from two replicate passage experiments (10 clones analyzed in each) and in a control passaged without
BILN 2061 (10 clones analyzed).
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shown that the NS3 protease domain can functionally cross-
interact with the NS4A cofactor from another genotype (13,
61), and NS3 protease genes from different genotypes cloned
into 1b/2a reference strain replicons do produce replication-
competent replicons. Attempts by other groups to include full-
length NS3/4A genes of other genotypes, including the heli-
case, in the 1b or 2a chimeric replicon system generally failed
to create efficiently replicating replicons, although in the latter
case, this may reflect a further compatibility restriction for the
helicase to be of the same genotype as the RNA polymerase
encoded by NS5B (3, 40).
The NS4A of genotype 2 has been shown to be much less
efficient in heterologous combinations than those of other ge-
notypes (61) and might explain why most of our recombinant
viruses containing the type 2a cofactor did not replicate effi-
ciently enough for detection. NS4As of genotypes 1a, 1b, 3a,
4a, 5a, and 6a are more similar to each other on the amino acid
sequence level than to genotype 2a (Fig. 3). Why, however,
genotype 5a protease forms a viable complex with the 2a back-
bone and the others do not remains unclear.
To resolve this compatibility issue, we included the corre-
sponding homologous genotype-specific NS4A cofactor in the
construction of the recombinant viruses (Fig. 3). This led to
viable chimeras for genotypes 1b, 2a, 3a, 5a, and 6a (Fig. 4).
J1a1a and J4a4a were impaired in their replication, but re-
placement of the NS3 protease gene in J4a4a with that of study
subjects allowed the generation of replication-competent 4a
recombinants (Fig. 4E and 5C). As expected, J2a2a replicated
most efficiently and immediately spread within the cell culture
(Fig. 4C), and J5a5a also spread to most cells within 2 days
(Fig. 4F), both comparable with the parental Jc1. Similarly, the
spread of Jc1 and these two recombinant viruses was also
accompanied by increased cell death, followed by proliferation
of HCV-NS5A-negative Huh7.5 cells, as described in previous
studies (14, 32, 45, 66). Reintroduction of attenuating muta-
tions (Table 2) allowed the generation of two recombinants,
which immediately and continuously infected the cell culture
(Fig. 6A and B). In contrast, the observed clearance of J1b1b
and J4a4a-19 after transfection is the likely consequence of
their failure to generate any infectious virus (Fig. 4B and E).
Unlike the other recombinant viruses, where spread is reduced
after an eclipse phase, J3a3a continuously infected about 80%
of the cell culture, with high frequencies of infected cells even
after 70 days of passaging in cell culture (Fig. 4D). As it has
been shown that the catalytic efficiencies of genotype 1a, 3a,
and 4a proteases are similar (13), the inability of genotype 1a
and some genotype 4a chimeras to replicate efficiently likely is
a consequence of the incompatibility between the NS3 pro-
tease/NS4A and the remaining type 2 sequence. The J6a6a
recombinant spread within the cell culture after an eclipse
phase, indicating adaptive mutations (Fig. 4F). The identified
mutation within the NS3 protease (V1040L) is a change at a
position with a highly conserved L/V/I polymorphism, and re-
introduction of it into the original recombinant rescued its
impaired replication kinetic (Fig. 6C) (4).
Even though the NS3 protease is considered one of the more
conserved proteins encoded by the HCV genome, different
genotypes do show substantial amino acid sequence variability
that potentially influences its structure and function (20, 27, 57,
60). Furthermore, it has been demonstrated that catalytic ef-
ficiencies within a subtype can vary widely, especially within
genotype 1b, whereas genotype 3a proteases showed the most
homogenous range of activities (13). Cloning of subject-de-
rived NS3 protease genes of genotype 1 into the 1b replicon
construct by Qi et al. has shown 2- to 7-fold differences in the
replication capacities of the constructs (40). To investigate the
influence of these intrasubtype sequence differences on chi-
mera viability, we directly amplified and cloned NS3 protease
gene sequences from study subject plasma samples into the
corresponding J1a1a, J1b1b, J3a3a, J4a4a, and J6a6a recombi-
nant viruses.
All three J3a3a recombinants constructed from the original
J3a3a-Gla and subject-derived protease genes generated viable
chimeras (Fig. 5B). Recombinants with diminished replication
kinetics could be rescued by introducing an adaptive L1663A
amino acid change within the membrane segment of NS4A
(Fig. 6D). The L1663A amino acid change likely is crucial for
efficient and continuous spread of the J3a3a recombinants, as
it was observed within the J3a3a-Gla recombinant as well after
43 days in cell culture (Table 2). Furthermore, L1663A is an
amino acid change toward the consensus genotype 2a se-
quence, suggesting adaptation to the Jc1 backbone sequence.
Similarly, NS3 proteases from study subjects infected with
genotypes 1b, 4a, and 6a were cloned into the corresponding
J1b1b, J4a4a, and J6a6a recombinants. Both J1b1b recombi-
nants replicated to the same extent as the prototype J1b1b,
indicating that patient-derived sequences can be easily
swapped and analyzed (Fig. 5A). Replacement of the NS3
protease gene of the J4a4a prototype recombinant with those
amplified from genotype 4a-infected subjects reversed the im-
paired replication phenotype in three (J4a4a-7, -8, and -19) out
of four cases (Fig. 5C). To which amino acid polymorphism
this discrepancy is due is unclear, as not only J4a4a and
J4a4a-10 but also J4a4a-19 have an amino acid polymorphism
that does not occur in any other sequence of our analyzed data
set. Replacement of the J6a6a NS3 protease with that of sub-
ject-derived genes resulted in replicating recombinants in both
cases (J6a6a-4 and -8) (Fig. 5D). J6a6a-4 immediately spread
within the cell culture and maintained a continuous infection,
whereas J6a6a-8 showed a replication profile similar to that of
prototype J6a6a. V1040L has been identified to be a crucial
adaptive change for J6a6a. J6a6a-8 also contains a Val at
position 1040, whereas J6a6a-4 contains an Ile, a bulkier amino
acid similar to Leu and which may underlie its improved rep-
lication kinetics.
In a similar manner, NS3 proteases from study subjects
infected with genotype 1a were cloned into the corresponding
J1a1a recombinants. The replication kinetics of the resulting
chimeras were very low or below detection limits, and none of
the viruses were able to acquire adaptive mutations; all Huh7.5
cell cultures were NS5A negative after 30 days. It has been
reported that the in vitro catalytic efficiency of the genotype 1a
NS3 protease is similar to those of 3a and 4a, both of whose
chimeras were replication competent in vitro (13). It is there-
fore unlikely that the J1a1a recombinants reproduce less effi-
ciently than those of J3a3a, J4a4a-7, and J4a4a-19 because of
differences in the enzymatic activity of the proteases. This
suggests that genotype 1a NS3 protease/NS4A are less com-
patible with the genotype 2a backbone than genotypes 1b, 3a,
4a, 5a, and 6a.
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Susceptibility and resistance development of different HCV
genotypes to PIs. The HCV-NS3 serine protease is essential
for viral replication and therefore an attractive target for
HCV-specific antiviral therapy (36). One of the first PIs devel-
oped, BILN 2061, was highly optimized for genotype 1 en-
zymes, making its binding more sensitive to sequence differ-
ences than substrate binding. However, it still shows Ki values
below 100 nM for nongenotype 1 NS3-4A proteins (55). Using
the intergenotype chimeras developed in the current study, we
showed J1b1b and J4a4a-19 to be more susceptible to BILN
2061 than J2a2a and J3a3a, as has been previously demon-
strated in vitro and in vivo (43, 55). Interestingly, J4a4a-19 and
J6a6a were equally as susceptible to BILN 2061 as J1b1b and
J5a5a, similarly to J2a2a and J5a5a. Experiments using ex-
pressed proteins showed similar IC50s for genotypes 1a, 1b, 4a,
5a, and 6a, whereas we observed a lower susceptibility level for
J5a5a toward BILN 2061 (31, 46). Equivalent differences in
susceptibility to BILN 2061 sensitivity were observed whether
determined by supernatant infectivity reduction or inhibition
of replication (Fig. 7 and 8). Differences in susceptibility ex-
tended even to variants within a genotype, with IC50s ranging
from around 130 nM to 310 nM in a panel of subject-derived
and reference genotype 3a protease sequences (Fig. 9). This 2-
to 3-fold difference may influence the effectiveness of antiviral
therapy.
The rapid selection of viral variants displaying drug-resistant
phenotypes is a major concern in HCV treatment. Several
resistant phenotypes have been observed in patients experienc-
ing viral rebound during therapy and in replicon experiments
(8, 23, 25, 28). Resistant mutations arising under BILN 2061
pressure have been described at the three main positions,
Arg155, Ala156, and Asp168 (8, 25, 28). In this study, we
identified several new in vitro resistance mutations in the NS3
protease gene of all 6 major genotypes. The dominant resis-
tance mutations observed against BILN 2061 occurred at po-
sition 168, where the Asp residue in genotypes 1b, 2a, 4a, and
6a changed to Gly/Glu/Val/Ala (genotypes 1b and 4a), Val/Tyr
(2a), and Val/Asn/Glu/His (6a). In the genotype 3a protease, a
replacement of Gln168 by Leu/Arg/Lys was detected, and in
the genotype 5a protease, Glu168 was replaced by Ala/Val/Gly.
Although conserved in position, a striking feature of this pat-
tern of mutation was the variable nature of the substituted
amino acid, suggesting great flexibility in the nature of the
structural disruption to the protease induced by these resis-
tance-associated changes. The observation that resistance-as-
sociated mutations in one genotype (such as D168E substitu-
tion in genotypes 1b and 6a) may occur as the wild-type amino
acid in another (genotype 5) is consistent with significant struc-
tural differences in the protease gene implied by the differ-
ences between genotypes in their susceptibility to inhibition by
BILN 2061.
Although further mutations at positions 155 and 156 have
been associated with BILN 2061 resistance (25, 28), substitu-
tions at position 156 were observed only in minority popula-
tions of genotype 1b and in genotype 4a. The exact phenotypic
effects of substitutions here and of further mutations poten-
tially associated with resistance, such as the Q195H mutation
in genotype 2a (Table 3), will require specific site-directed
mutagenesis and IC50 determinations, along with comparisons
of resistance profiles of the many different substitutions and
genotype backgrounds at position 168. Progress toward char-
acterization of these mutations and combinations will in the
long term provide the necessary data for the development of
genotypic drug resistance databases analogous to those devel-
oped for human immunodeficiency virus type 1.
In summary, we have developed a full-length HCV cell cul-
ture system, which allows the investigation of protease gene
function in all six genotypes, a much greater range than the
genotypes 2a and 1a full-length replication-competent clones
described previously (26, 34, 59, 64). The developed system
represents a powerful tool to study the NS3 protease within the
full viral life cycle and adds to the currently available JFH1-
based systems for the study of the nonstructural genes (14, 15,
21, 38, 45, 65). Overall, this system has allowed us to demon-
strate that different NS3 proteins react differently to the same
protease inhibitor. Any protease inhibitor identified in high-
throughput screening can be evaluated for its efficacy on dif-
ferent genotypes and treatments designed according to the
outcome. Passaging the recombinants in subinhibitory concen-
trations of antiviral drugs allowed us to identify potential re-
sistance mutations to BILN 2061 and will therefore be of
considerable value in preclinical assessment of resistance in-
duction and genotypic variability for newly developed com-
pounds.
The ease with which protease gene sequences amplified di-
rectly from clinical specimens can be inserted in the expression
vector of the appropriate genotypes allows for the first time
direct monitoring of antiviral drug inhibition for specific pro-
teases through assessment of reduction in both supernatant
infectivity and replication kinetics. Protease genes from study
subjects naïve to treatment can then easily be assessed for
sensitivity to a range of antiviral drugs and screened for pre-
occurring resistance mutations, as well as providing a pheno-
typic assay for rapid assessment of emerging resistance during
therapy and the influence of specific mutations on treatment
outcome.
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